{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:34Z","timestamp":1790806834889,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40265-024-02101-9","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:51:23Z","timestamp":1731012683000},"page":"1463-1474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efgartigimod: A Review in Generalised Myasthenia Gravis"],"prefix":"10.1007","volume":"84","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"1","key":"2101_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15\u201332.","journal-title":"CNS Drugs"},{"issue":"8","key":"2101_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"3","key":"2101_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022;19(3):897\u2013910.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"2101_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, et al. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1597.","journal-title":"J Clin Med"},{"issue":"1","key":"2101_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102712","volume":"20","author":"AM Lascano","year":"2021","unstructured":"Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20(1): 102712.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2101_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"Y-A Heo","year":"2022","unstructured":"Heo Y-A. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138.","journal-title":"Drugs"},{"issue":"5","key":"2101_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"Y-A Heo","year":"2023","unstructured":"Heo Y-A. Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs. 2023;37(5):467\u201373.","journal-title":"CNS Drugs"},{"key":"2101_CR8","unstructured":"argenx US. VYVGART\u00ae (efgartigimod alfa-fcab) injection, for intravenous use: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8aefc8e3-26d6-4ff6-aab9-a7542927e084. Accessed 18 Sep 2024."},{"key":"2101_CR9","unstructured":"argenx US. VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use: US prescribing information. 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7104d9e5-9910-47f5-9a93-741ac50f43b6. Accessed 18 Sep 2024."},{"key":"2101_CR10","unstructured":"argenx. Vyvgart (efgartigimod alfa): EU summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyvgart. Accessed 18 Sep 2024."},{"key":"2101_CR11","unstructured":"Pharmaceutical Technology. China NMPA approves Zai Lab-argenx's efgartigimod alfa for gMG [media release]. 17 Jul 2024. https:\/\/www.pharmaceutical-technology.com."},{"key":"2101_CR12","unstructured":"Pharmaceutical Technology. argenx's VYVDURA gains approval in Japan for gMG treatment [media release]. 19 Jan 2024. https:\/\/www.pharmaceutical-technology.com."},{"issue":"10","key":"2101_CR13","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386.","journal-title":"J Clin Invest"},{"key":"2101_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","volume":"317","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Plomp JJ, van Es IE, et al. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol. 2019;317:133\u201343.","journal-title":"Exp Neurol"},{"key":"2101_CR15","unstructured":"Vu T, Howard Jr J, Li Y, et al. Dose selection and clinical development of efgartigimod PH20 subcutaneous in patients with generalized myasthenia gravis [poster no. 270]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023."},{"issue":"23","key":"2101_CR16","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"issue":"7","key":"2101_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"1284444","key":"2101_CR18","first-page":"1","volume":"14","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023;14(1284444):1\u201314.","journal-title":"Front Neurol"},{"key":"2101_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Vu T, Li G, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics. 2024. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00378.","journal-title":"Neurotherapeutics"},{"key":"2101_CR20","unstructured":"Azar A, Sleasman JW, Verhamme F, et al. Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod [poster no. 1]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023."},{"issue":"8","key":"2101_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","volume":"55","author":"JT Guptill","year":"2022","unstructured":"Guptill JT, Sleasman JW, Steeland S, et al. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis. Autoimmunity. 2022;55(8):620\u201331.","journal-title":"Autoimmunity"},{"issue":"7","key":"2101_CR22","doi-asserted-by":"publisher","first-page":"S329","DOI":"10.1016\/j.jval.2022.04.230","volume":"25","author":"C Qi","year":"2022","unstructured":"Qi C, Dewilde S, Gelinas D, et al. Hospitalization and exacerbation estimates of efgartigimod vs. conventional therapy in generalized myasthenia gravis patients: a post-hoc analysis of the phase 3 ADAPT study [abstract no. CO135 plus poster]. Value Health. 2022;25(7):S329.","journal-title":"Value Health."},{"issue":"Suppl 1","key":"2101_CR23","first-page":"358","volume":"30","author":"S Hoffmann","year":"2023","unstructured":"Hoffmann S, Zhao S, Callewaert E, et al. Gender-specific analysis of efgartigimod efficacy in patients with gMG: subanalysis of the randomised phase 3 ADAPT trial [abstract no. EPO-055 plus poster]. Eur J Neurol. 2023;30(Suppl 1):358.","journal-title":"Eur J Neurol"},{"issue":"Suppl. 1","key":"2101_CR24","first-page":"357","volume":"30","author":"S Hoffmann","year":"2023","unstructured":"Hoffmann S, Meisel A, Attarian S, et al. Efgartigimod demonstrates consistent magnitude of response across subgroups of patients with gMG [abstract no. EPO-054 plus poster]. Eur J Neurol. 2023;30(Suppl. 1):357\u20138.","journal-title":"Eur J Neurol"},{"issue":"e16098","key":"2101_CR25","first-page":"1","volume":"31","author":"V Bril","year":"2024","unstructured":"Bril V, Howard JF Jr, Karam C, et al. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. Eur J Neurol. 2024;31(e16098):1\u20139.","journal-title":"Eur J Neurol"},{"issue":"Suppl. 1","key":"2101_CR26","first-page":"568","volume":"30","author":"C Rozsa","year":"2023","unstructured":"Rozsa C, Sacc\u00e0 F, De Bleecker J, et al. Efgartigimod demonstrates consistent improvements in patients with gMG regardless of prior treatment failures [abstract no. EPO-388 plus poster]. Eur J Neurol. 2023;30(Suppl. 1):568.","journal-title":"Eur J Neurol"},{"issue":"17 Suppl. 2","key":"2101_CR27","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1212\/WNL.0000000000203722","volume":"100","author":"V Bril","year":"2023","unstructured":"Bril V, Vu T, Brauer E, et al. Efgartigimod demonstrates consistent improvements in generalized myasthenia gravis patients of shorter disease duration [abstract no. P1\u20135.015 plus poster]. Neurology. 2023;100(17 Suppl. 2):4070.","journal-title":"Neurology"},{"key":"2101_CR28","unstructured":"Pulley M, Pasnoor M, Gelinas D, et al. The effect of obesity in efficacy and safety in the ADAPT trial of efgartigimod for generalized myasthenia gravis [poster no. 194]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2022."},{"issue":"4","key":"2101_CR29","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","volume":"270","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Barnett C, Vu T, et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). J Neurol. 2023;270(4):2096\u2013105.","journal-title":"J Neurol"},{"issue":"4","key":"2101_CR30","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s12325-023-02437-w","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Qi CZ, Phillips G, et al. Association between myasthenia gravis-activities of daily living (MG-ADL) and EQ-5D-5L utility values: the additional effect of efgartigimod on utilities. Adv Ther. 2023;40(4):1818\u201329.","journal-title":"Adv Ther"},{"issue":"5","key":"2101_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mus.27974","volume":"68","author":"N Katyal","year":"2023","unstructured":"Katyal N, Halldorsdottir K, Govindarajan R, et al. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023;68(5):762\u20136.","journal-title":"Muscle Nerve"},{"key":"2101_CR32","unstructured":"Qi C, Narayanaswami P, Wolfe G, et al. Real-world outcomes of patients living with generalized myasthenia gravis initiating efgartigimod treatment in the United States [poster]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023."},{"issue":"1","key":"2101_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","volume":"69","author":"M Singer","year":"2024","unstructured":"Singer M, Khella S, Bird S, et al. Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve. 2024;69(1):87\u201392.","journal-title":"Muscle Nerve"},{"key":"2101_CR34","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.31.24302082","author":"J Moniz Dion\u00edsio","year":"2024","unstructured":"Moniz Dion\u00edsio J, Ambrose P, Burke G, et al. Efgartigimod efficacy and safety in refractory myasthenia gravis: UK\u2019s first real-world experience. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.01.31.24302082.","journal-title":"medRxiv."},{"key":"2101_CR35","first-page":"1","volume":"e16189","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, et al. Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center. Eur J Neurol. 2024;e16189:1\u201310.","journal-title":"Eur J Neurol"},{"key":"2101_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12588-7","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024. https:\/\/doi.org\/10.1007\/s00415-024-12588-7.","journal-title":"J Neurol"},{"key":"2101_CR37","doi-asserted-by":"publisher","first-page":"1407418","DOI":"10.3389\/fneur.2024.1407418","volume":"15","author":"P Wang","year":"2024","unstructured":"Wang P, Zhang B, Yin J, et al. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol. 2024;15:1407418.","journal-title":"Front Neurol"},{"issue":"3","key":"2101_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y, et al. Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract. 2024;14(3): e200276.","journal-title":"Neurol Clin Pract."},{"key":"2101_CR39","doi-asserted-by":"crossref","unstructured":"Goyal N, Qi C, Stone J, et al. Real-world reduction in oral corticosteroid utilization following efgartigimod initiation in patients living with generalized myasthenia gravis [oral presentation]. In: American Academy of Neurology (AAN) Annual Meeting. 2024.","DOI":"10.1212\/WNL.0000000000205871"},{"key":"2101_CR40","doi-asserted-by":"crossref","unstructured":"Howard Jr JF, Li Y, Vu T, et al. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in participants with generalized myasthenia gravis: interim results of the ADAPT-SC+ study [poster 008]. In: American Academy of Neurology (AAN) Annual Meeting. 2024.","DOI":"10.1212\/WNL.0000000000206401"},{"key":"2101_CR41","doi-asserted-by":"crossref","unstructured":"Howard Jr JF, Vu T, De Bleecker J, et al. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in participants with generalized myasthenia gravis: interim analysis of anti-acetylcholine receptor autoantibody seronegative participants in the ADAPT-SC+ study [poster no. 151]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023.","DOI":"10.1212\/WNL.0000000000206401"},{"key":"2101_CR42","unstructured":"Vu T, Howard Jr J, Korobko D, et al. Subcutaneous efgartigimod PH20 treatment in participants with generalized myasthenia gravis in ADAPT-SC+: interim analyses on quality of life, efficacy, tolerability, and long-term safety [presentation]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023."},{"key":"2101_CR43","doi-asserted-by":"crossref","unstructured":"Podhorna J, Ward C, Lee I, et al. Analysis of serious infections and malignancy risk in myasthenia gravis: a US claims database study [poster 007]. In: American Academy of Neurology (AAN) Annual Meeting. 2024.","DOI":"10.1212\/WNL.0000000000206555"},{"issue":"4","key":"2101_CR44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"14","key":"2101_CR45","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Rozanolixizumab: first approval. Drugs. 2023;83(14):1341\u20137.","journal-title":"Drugs"},{"issue":"3","key":"2101_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376.","journal-title":"Drugs"},{"issue":"8","key":"2101_CR47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40265-023-01877-6","volume":"83","author":"C Kang","year":"2023","unstructured":"Kang C. Ravulizumab: a review in generalised myasthenia gravis. Drugs. 2023;83(8):717\u201323.","journal-title":"Drugs"},{"issue":"1","key":"2101_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M. Zilucoplan: first approval. Drugs. 2024;84(1):99\u2013104.","journal-title":"Drugs"},{"key":"2101_CR49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s40267-024-01095-4","volume":"40","author":"C Fenton","year":"2024","unstructured":"Fenton C, Kang C. Several more myasthenia gravis therapy options now available. Drugs Ther Perspect. 2024;40:350\u20132.","journal-title":"Drugs Ther Perspect."},{"key":"2101_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:1\u201331.","journal-title":"Ther Adv Neurol Disord"},{"key":"2101_CR51","first-page":"1","volume":"e16229","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol. 2024;e16229:1\u201313.","journal-title":"Eur J Neurol"},{"key":"2101_CR52","doi-asserted-by":"crossref","unstructured":"Bril V, Hussain Y, Gwathmey K, et al. Fixed cycle and every-other-week dosing of intravenous efgartigimod for generalized myasthenia gravis: part A of ADAPT NXT [poster 010]. In: American Academy of Neurology (AAN) Annual Meeting. 2024.","DOI":"10.1212\/WNL.0000000000206537"},{"issue":"1280226.","key":"2101_CR53","first-page":"1","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z, et al. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol. 2023;14(1280226.):1\u201314.","journal-title":"Front Immunol"},{"key":"2101_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2024;38:93\u2013104.","journal-title":"CNS Drugs"},{"key":"2101_CR55","unstructured":"Meuth S, Hagenacker T, Scheiner C, et al. Matching-adjusted indirect comparison of ravulizumab\/efgartigimod in generalised myasthenia gravis: timepoint challenges [abstract no. EPO-225]. Eur J Neurol. 2023;30(Suppl. 1):467."},{"issue":"12","key":"2101_CR56","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, et al. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30(12):3854\u201367.","journal-title":"Eur J Neurol"},{"key":"2101_CR57","unstructured":"Wolfe G, Sacc\u00e0 F, Phillips G, et al. Network meta-analysis of treatment options in generalized myasthenia gravis: impact on health-related quality of life outcome [poster]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2023."},{"key":"2101_CR58","unstructured":"Sacca F, Dewilde S, Nivelle E, et al. Combining clinical trial and real-world data to model the benefit of efgartigimod on productivity losses [abstract no. PS05.02]. J Neuromuscul Dis. 2022;9(Suppl.):S108\u20109."},{"key":"2101_CR59","doi-asserted-by":"crossref","unstructured":"Qi C, Wang J, Yang H, et al. Numbers needed to treat and costs per improved outcome among treatments for myasthenia gravis [abstract no. EE121 plus poster]. Value Health. 2022;25(7):S358.","DOI":"10.1016\/j.jval.2022.04.372"},{"key":"2101_CR60","doi-asserted-by":"crossref","unstructured":"Siddiqi Z, Genge A, Qi CZ, et al. Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) in Canada [poster P4.003]. In: American Academy of Neurology (AAN) Annual Meeting. 2024.","DOI":"10.1212\/WNL.0000000000208162"},{"issue":"1","key":"2101_CR61","first-page":"119","volume":"28","author":"JA Tice","year":"2022","unstructured":"Tice JA, Touchette DR, Lien PW, et al. The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis. J Manag Care Spec Pharm. 2022;28(1):119\u201324.","journal-title":"J Manag Care Spec Pharm"},{"key":"2101_CR62","unstructured":"National Institute for Health and Care Excellence. Draft guidance consultation: efgartigimod for treating generalised myasthenia gravis. 2023. https:\/\/www.nice.org.uk\/guidance\/GID-TA10986\/documents\/draft-guidance-3. Accessed 18 Sep 2024."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02101-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02101-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02101-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:43:13Z","timestamp":1732765393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02101-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02101-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"17 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}